This article is freely available to all

Article Abstract

As palliative treatments for Alzheimer’s disease proliferate, the focus of therapeutics turns to drugs withthe potential to alter course. Evidence is reviewed, suggesting that there is biological plausibility to utilizinganti-inflammatory agents, antioxidants, free-radical scavengers, estrogen preparations, and perhaps cholinomimetics.This range of possibilities leads to an optimistic assessment of the likelihood for altering the courseor delaying the onset of Alzheimer’s disease.